retatrutide phase 3 triumph just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide dose: the complete guide

These promising findings position tirzepatide as a transformative therapy for metabolic and endocrine disorders

All providers in our network are licensed in your state of residence

This article explores the biology of GLP-1, reviews current and emerging therapies, and examines their implications for the future of drug discovery and development

They mimic a hormone that the body is supposed to produce naturally, which increases the amount of insulin released by the pancreas in order to control blood sugar

It does not show direct damage to hair follicles, and most cases of shedding are linked to metabolic changes rather than to the medication itself

Managing side effects at the starting dose Even at the lowest starting doses, some people experience side effects